^
Association details:
| Biomarker: | LMNA-NTRK1 fusion + NTRK1 G595R |
|---|---|
| Cancer: | Cholangiocarcinoma |
| Drug: | Augtyro (repotrectinib) (ALK inhibitor, Multi-tyrosine kinase inhibitor, ROS1 inhibitor, Trk inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1119 - Molecular characteristics of repotrectinib that enable potent inhibition of TRK fusion proteins and broad mutant selectivity
Published date:
03/10/2021
Excerpt:
Analysis of the first protein structure of a kinase harboring a common SFM (TRKA G595R)…In the clinic, tumor regression was observed with repotrectinib treatment of a larotrectinib-resistant cholangiocarcinoma patient with both LMNA-TRKA GKM and SFM mutations...Repotrectinib has shown responses in patients with TRK driven tumors with or without resistant mutations in the ongoing global registrational TRIDENT-1 study.
